RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1743415
Synthesis and Biological Evaluation of a Series of Novel 1-(3-((6-Fluoropyridin-3-yl)oxy)propyl)piperazines as Dopamine/Serotonin Receptor Agonists
Abstract
Evidence suggested that the use of partial dopamine D2/D3 receptor agonists may be a better choice for the treatment of Parkinson's disease (PD), and the stimulation of 5-HT1A receptors (mainly via nondopaminergic mechanisms) alleviates motor and nonmotor disorders of PD, implying that the multitarget approach may provide a double bonus for the treatment of the disease. In this study, 20 novel 1-(3-((6-fluoropyridin-3-yl)oxy)propyl)piperazine derivatives were designed and synthesized using a bioisosterism approach, and their activities for D2/D3/5-HT1A receptors were further tested. The results showed that several compounds exhibited a multitarget combination of D2/5-HT1A agonism. Compounds 7b and 34c showed agonistic activities on D2/D3/5-HT1A receptor. The EC50 value of 7b for D2/D3/5-HT1A receptor were 0.9/19/2.3 nmol/L, respectively; and the EC50 value of 34c for D2/D3/5-HT1A receptor were 3.3/10/1.4 nmol/L, respectively. In addition, 34c exhibited good metabolic stability (the half-life T 1/2 = 159.7 minutes) in vitro, which is of great significance for the further exploration of multitarget anti-PD drugs.
Ethics Statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Publikationsverlauf
Eingereicht: 22. November 2021
Angenommen: 27. Januar 2022
Artikel online veröffentlicht:
31. März 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993; 12 (04) 219-228
- 2 Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 2020; 323 (06) 548-560
- 3 Jost WH. Autonomic dysfunctions in idiopathic Parkinson's disease. J Neurol 2003; 250 (Suppl. 01) I28-I30
- 4 Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 2014; 29 (05) 634-650
- 5 Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012; 46 (03) 581-589
- 6 Schapira AH. Etiology and pathogenesis of Parkinson disease. Neurol Clin 2009; 27 (03) 583-603 , v
- 7 Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust 2018; 208 (09) 404-409
- 8 Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR. Parkinson's: a syndrome rather than a disease?. J Neural Transm (Vienna) 2017; 124 (08) 907-914
- 9 Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020; 91 (08) 795-808
- 10 Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1 (7954): 292-296
- 11 Torti M, Bravi D, Vacca L, Stocchi F. Are all dopamine agonists essentially the same?. Drugs 2019; 79 (07) 693-703
- 12 Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311 (16) 1670-1683
- 13 Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf 2016; 15 (02) 181-198
- 14 Stocchi F. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 04) S54-S57
- 15 Das B, Vedachalam S, Luo D, Antonio T, Reith ME, Dutta AK. Development of a highly potent D2/D3 agonist and a partial agonist from structure-activity relationship study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: implication in the treatment of Parkinson's disease. J Med Chem 2015; 58 (23) 9179-9195
- 16 Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002; 58 (4, Suppl 1): S1-S8
- 17 Cerri S, Siani F, Blandini F. Investigational drugs in phase I and phase II for Levodopa-induced dyskinesias. Expert Opin Investig Drugs 2017; 26 (07) 777-791
- 18 Ohno Y, Shimizu S, Tokudome K, Kunisawa N, Sasa M. New insight into the therapeutic role of the serotonergic system in Parkinson's disease. Prog Neurobiol 2015; 134: 104-121
- 19 Miyazaki I, Asanuma M. Serotonin 1A receptors on astrocytes as a potential target for the treatment of Parkinson's disease. Curr Med Chem 2016; 23 (07) 686-700
- 20 Shimizu S, Ohno Y. Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT(1A) receptors. Aging Dis 2013; 4 (01) 1-13
- 21 Jones CA, Johnston LC, Jackson MJ. et al. An in vivo pharmacological evaluation of pardoprunox (SLV308)–a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol 2010; 20 (08) 582-593
- 22 Glennon JC, Van Scharrenburg G, Ronken E. et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 2006; 60 (08) 599-608
- 23 Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp Neurol 2010; 226 (02) 320-327
- 24 Löber S, Hübner H, Tschammer N, Gmeiner P. Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. Trends Pharmacol Sci 2011; 32 (03) 148-157
- 25 Yang F, Jiang X, Li J. et al. Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics. Bioorg Med Chem Lett 2016; 26 (13) 3141-3147
- 26 Huang L, Gao L, Zhang X. et al. Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics. Bioorg Med Chem Lett 2020; 30 (20) 127506
- 27 Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther 2015; 352 (03) 480-493
- 28 Xu M, Wang Y, Yang F. et al. Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs. Bioorg Med Chem Lett 2018; 28 (04) 606-611
- 29 Casey AB, Canal CE. Classics in chemical neuroscience: aripiprazole. ACS Chem Neurosci 2017; 8 (06) 1135-1146
- 30 Maeda K, Stensbol TB, Hentzer M. et al. In vitro pharmacological profile of brexpiprazole, a novel serotonin-dopamine activity modulator. Paper presented at: 69th Annual Meeting Society of Biological Psychiatry (SOBP); May 08, 2014; New York, United States
- 31 Yamashita H, Matsubara J, Oshima K. et al. Preparation of benzo[b]thiophen-4-yl-piperazine and related compounds as antipsychotic agents for the treatment of mental disorders. WO Patent 2007026959 A2. March, 2007
- 32 Xu JW, Qi YL, Wu JW, Yuan RX, Chen XW, Li JQ. Synthesis and biological evaluation of novel antipsychotic trans-4-(2-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)ethyl)cyclohexan-1-amine derivatives targeting dopamine/serotonin receptor subtypes. Bioorg Med Chem Lett 2021; 31: 127681